Business Context and Reporting Period
Vera Therapeutics, Inc. filed this Form 8-K under Item 5.02 to report a change in its board leadership and director composition. The report date was April 7, 2022; the filing was signed April 12, 2022.
Board and Governance Changes
- Kurt von Emster resigned as a director and Chair of the Board, effective as of the 2022 Annual Meeting of Stockholders.
- The company stated that Mr. von Emster’s resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.
- On April 11, 2022, the Board appointed Michael M. Morrissey, Ph.D., as a Class II director and Chair of the Board, effective as of the Annual Meeting Date. His initial term expires at the 2023 Annual Meeting of Stockholders.
- Dr. Morrissey was also appointed to the Audit Committee and Nominating and Corporate Governance Committee, succeeding Mr. von Emster.
Compensation and Equity Awards
- Dr. Morrissey received a nonstatutory option to purchase 40,000 shares of Class A common stock, replacing the standard new-director initial grant of 19,850 shares.
- The option vests monthly over three years, subject to continued service, and is otherwise governed by the company’s Non-Employee Director Compensation Policy.
- For 2022, prorated annual cash retainers include $65,000 for Board Chair service, $7,500 for Audit Committee service, and $4,000 for Nominating Committee service.
- Beginning with the 2023 Annual Meeting, Dr. Morrissey will be eligible for an annual option covering 9,925 shares. The award will vest on the earlier of the first anniversary of grant or the next annual meeting, subject to continued service.
- Dr. Morrissey will enter into the company’s standard indemnification agreement effective as of the Annual Meeting Date.
Financial Metrics, Liquidity, and Outlook
This filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics. It also does not include management’s financial outlook.
Material Changes, Risks, and Unusual Items
The material change is the transition in Board Chair and committee membership. The enhanced initial equity award and related director compensation are notable governance and compensation items. The filing reports no arrangements or understandings relating to Dr. Morrissey’s selection and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the date of the 2022 Annual Meeting and the effective date of the leadership transition.
- Review the terms, exercise price, vesting conditions, and accounting impact of the 40,000-share option grant.
- Confirm the prorated 2022 cash retainers and the applicable Non-Employee Director Compensation Policy.
- Assess any subsequent changes to Board composition, committee assignments, or director compensation in later filings.